Your browser doesn't support javascript.
loading
Thirty-day Treatment Continuation After Audio-only Buprenorphine Telehealth Initiation.
Wunsch, Caroline; Wightman, Rachel; Pratty, Claire; Jacka, Brendan; Hallowell, Benjamin D; Clark, Seth; Davis, Corey S; Samuels, Elizabeth A.
Afiliação
  • Wunsch C; From the Department of Internal Medicine, Alpert Medical School of Brown University, Providence, RI (CW, SC); Department of Emergency Medicine, Alpert Medical School of Brown University, Providence, RI (RW, EAS); Department of Epidemiology, Brown School of Public Health, Providence, RI (CP, BJ, EAS); Rhode Island Department of Health, Providence, Rhode Island (BDH); Department of Psychiatry and Human Behavior, The Warren Alpert Medical School of Brown University, Providence, RI, United States of
J Addict Med ; 17(2): 206-209, 2023.
Article em En | MEDLINE | ID: mdl-36102540
ABSTRACT

OBJECTIVES:

Before the coronavirus disease 2019 pandemic, federal law required in-person evaluation before buprenorphine initiation. Regulatory changes during the pandemic allow for buprenorphine initiation by audio-only or audiovisual telehealth. Little is known about treatment engagement after buprenorphine initiation conducted via audio-only telehealth.

METHODS:

A retrospective cohort study of 94 individuals who received initial treatment through an audio-only encounter between April 2020 and February 2021 was performed. Participant demographics, substance use history, withdrawal symptoms, 30-day treatment engagement, and adverse outcomes were determined by an electronic chart and REDcap database review. Subsequent buprenorphine prescriptions filled within 30 days of the initial encounter were tracked through the Rhode Island Prescription Drug Monitoring Program.

RESULTS:

Buprenorphine was prescribed for 94 individuals. Most (92 of 94 [97.9%]) filled their prescription within 30 days. Most had previously taken buprenorphine, including prescribed (42 of 92 [45.7%]) and nonprescribed (58 of 92 [63.0%]). Two thirds were in opioid withdrawal at the time of the call (61 of 92 [66.3%]) with a mean Subjective Opioid Withdrawal Scale of 26.8 (range, 4-57). Four individuals experienced precipitated withdrawal (4 of 94 [4.3%]), and 2 reported persistent withdrawal at their follow-up visit (2 of 94 [2.1%]). More than 70% filled a subsequent prescription for buprenorphine within 30 days of the end of their hotline prescription (65 of 92 [70.7%]), on average of 5.88 days (range, 0-28) after completion of their telehealth prescription.

CONCLUSIONS:

Expanding telehealth-delivered buprenorphine care has the potential to address treatment gaps and facilitate delivery of on-demand services during peak motivation. This evaluation of audio-only buprenorphine initiation found high rates of unobserved buprenorphine initiation and treatment continuation with low rates of complications.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 4_TD / 8_ODS3_consumo_sustancias_psicoactivas Base de dados: MEDLINE Assunto principal: Síndrome de Abstinência a Substâncias / Buprenorfina / Telemedicina / COVID-19 / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: J Addict Med Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 4_TD / 8_ODS3_consumo_sustancias_psicoactivas Base de dados: MEDLINE Assunto principal: Síndrome de Abstinência a Substâncias / Buprenorfina / Telemedicina / COVID-19 / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: J Addict Med Ano de publicação: 2023 Tipo de documento: Article